Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human PrimatesPRNewsWire • 09/28/21
Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare ConferencePRNewsWire • 09/27/21
Soligenix Develops Groundbreaking Vaccine Platform to Target Future PandemicsNewsfile Corp • 09/14/21
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell LymphomaPRNewsWire • 09/09/21
Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch ReviewPRNewsWire • 08/24/21
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus DiseasesPRNewsWire • 08/23/21
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine CandidatesPRNewsWire • 08/18/21
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial ResultsPRNewsWire • 08/13/21
Offering New Hope for a Rare Form of non-Hodgkin's Lymphoma: A Discussion with Dr. Ellen Kim on HyBryte(TM) from SoligenixNewsfile Corp • 07/06/21
HyBryte™ Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual MeetingPRNewsWire • 06/22/21
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines AgencyPRNewsWire • 06/10/21
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer ProgramPRNewsWire • 06/09/21
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin CompositionPRNewsWire • 05/20/21
Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial ResultsPRNewsWire • 05/17/21
Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryteBenzinga • 05/10/21